MC
HAE icon

Miles Capital’s Haemonetics HAE Stock Holding History

Miles Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-11,791
Closed -$497K – 110
2013
Q4 		$497K Buy
+11,791
New +$485K 0.24% 85

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Miles Capital's HAE Position: Q1 2014 in Review

Miles Capital sold out of Haemonetics (HAE) in Q1 2014, closing a stake of 11,791 shares — an estimated $497K sold.

Miles Capital first reported a position in HAE in Q4 2013 and held it in 1 quarter. The position peaked at $497K in Q4 2013. 192 funds tracked by Wall St. Rank hold HAE as of Q1 2014.

  • Miles Capital reported no remaining Haemonetics position as of Q1 2014 after selling out during the quarter.
  • Miles Capital sold 11,791 Haemonetics shares in Q1 2014, an estimated $497K.
  • Miles Capital first reported a position in Haemonetics in Q4 2013 and held it in 1 quarter.
  • Miles Capital's Haemonetics position peaked at $497K in Q4 2013.
  • 192 funds tracked by Wall St. Rank held Haemonetics as of Q1 2014.

Based on Miles Capital's 13F filing for Q1 2014, filed 13 May 2014.